Lantern Pharma is a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic date to streamline the drug development process and to identify patients who will benefit from their targeted oncology therapies. Their portfolio of therapies consists of compounds that others have tried, but failed, to develop into an approved commercialized drug. Additionally, they develop new compounds with the assistance of their A.I. platform (RADR) and biomarker driven approach. The Company is currently developing four therapeutic programs.
Lantern Pharma is a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic date to streamline the drug development process and to identify patients who will benefit from their targeted oncology therapies. Their portfolio of therapies consists of compounds that others have tried, but failed, to develop into an approved commercialized drug. Additionally, they develop new compounds with the assistance of their A.I. platform (RADR) and biomarker driven approach. The Company is currently developing four therapeutic programs.
Outsourcing in Drug Development: The Contract Research (Clinical Trial) MarketMarketResearch.com
The cost and time of developing and bringing a drug to market is over $1.3 billion and often takes as long as 15 years, if not longer. Because of this, major pharmaceutical marketers continue to outsource stages of development, and over the years Kalorama Information has observed this process. In past editions of our outsourcing market studies, we found that outsourcing moved from "should" to "must." for manufacturers. This trend has only continued in the past two years. Contract Research Organizations (CROs) and other entities can expect growing demand for their services.
The demand for new drugs remains unabated, but the cost and need to bring those drugs to market is ever-increasing and intensifying. A key cost driver is the large number of failures during the expensive clinical trial phases. Driven by pressures to reduce costs, companies are increasingly implementing outsourcing strategies to increase revenues through faster drug development. By decreasing their in-house facilities and staff, and outsourcing more of their R&D functions, pharmaceutical and biotechnology companies are reshaping the drug development services industry.
Kalorama Information's Outsourcing in Drug Development: The Contract Research (Clinical Trial) Market is the third edition of this study of the drivers for outsourcing drug development, the companies involved in this market and the opportunity for revenues.
Critical Outcome Technologies Inc. streamlines drug discovery - dramatically reducing the time and cost to bring new drugs to market. The Company is listed on the TSX Venture Exchange (ticker symbol: COT).
Lantern Pharma is a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic date to streamline the drug development process and to identify patients who will benefit from their targeted oncology therapies. Their portfolio of therapies consists of compounds that others have tried, but failed, to develop into an approved commercialized drug. Additionally, they develop new compounds with the assistance of their A.I. platform (RADR) and biomarker driven approach. The Company is currently developing four therapeutic programs.
1. R-Pharm Drugs Technology is one of the leading Russian
pharmaceutical companies in R&D and Manufacturing
of generic and original drug formulations.
Delivering hope is
not our profession.
It’s our passion.
2. Our Mission
At R-Pharm DrugsTech we
strive to develop the highest
quality affordable Generic
Drugs in Russia and Overseas.
• Cost-effective production of high-quality Generic Drugs
• Development of effective Brand Drugs with increased safety for
patients
• High-Profile International Scientific Collaborations in Drug Discovery
• New commercial opportunities for international expansion
3. Disclaimer
This document may include claims that may appear as “forward-looking
statements”. Such statements inherently involve risks and uncertainties, ac-
tual future results may differ substantially from those expressed or implied
by such forward-looking statements. Factors causing or contributing to such
differences include, but are not limited to: any legal or regulatory challenges
to the settlement; strategies by competitors or other third parties to delay or
prevent product introductions; risks inherent in legal and regulatory processes;
and the other risks detailed in company’s periodic filings. The company under-
takes no obligation to update these statements for revisions or changes after
the date of this release.
4. DRUGS TECHNOLOGY LLC
R-Pharm Group of Companies
141400, Moscow Urban Area
Industrial Town of Khimki
Rabochaya Street 2A, Bldg.1
www.drugsformulation.ru
+7 495 225 6200
